We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-1.31%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.3B
AUM Growth
-$2.36B
Cap. Flow
-$405M
Cap. Flow %
-2.65%
Top 10 Hldgs %
84.69%
Holding
128
New
12
Increased
7
Reduced
17
Closed
13

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$36M
2
AKRO
Akero Therapeutics
AKRO
+$34.4M
3
VERU icon
Veru
VERU
+$23.2M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$22.8M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$21.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$311M
2
INSM icon
Insmed
INSM
+$51.2M
3
LEGN icon
Legend Biotech
LEGN
+$47.1M
4
KRYS icon
Krystal Biotech
KRYS
+$27.9M
5
PACB icon
Pacific Biosciences
PACB
+$24.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRON
76
DELISTED
Kronos Bio
KRON
$5.16M 0.03%
+1,539,616
New +$6.95M
CYT
77
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$5.08M 0.03%
2,643,640
– –
SRZN icon
78
Surrozen
SRZN
$224M
$5.05M 0.03%
166,667
– –
EWTX icon
79
Edgewise Therapeutics
EWTX
$4.27B
$4.92M 0.03%
500,000
– –
FATE icon
80
Fate Therapeutics
FATE
$276M
$4.83M 0.03%
+215,695
New +$6.23M
STOK icon
81
Stoke Therapeutics
STOK
$1.84B
$4.74M 0.03%
+369,327
New +$5.89M
NTRA icon
82
Natera
NTRA
$36.3B
$4.38M 0.03%
100,000
– –
RVMD icon
83
Revolution Medicines
RVMD
$38.5B
$4.38M 0.03%
222,222
– –
ALLK
84
DELISTED
Allakos
ALLK
$4.3M 0.03%
703,050
– –
EIGR
85
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.07M 0.03%
+17,995
New +$4.42M
PMVP icon
86
PMV Pharmaceuticals
PMVP
$56.5M
$3.83M 0.03%
+322,024
New +$4.65M
IPSC icon
87
Century Therapeutics
IPSC
$364M
$3.67M 0.02%
+370,587
New +$3.9M
HOOK
88
DELISTED
HOOKIPA Pharma
HOOK
$3.22M 0.02%
240,048
– –
LONA
89
LeonaBio Inc
LONA
$65.3M
$3.09M 0.02%
104,083
– –
MGNX icon
90
MacroGenics
MGNX
$233M
$3.09M 0.02%
892,579
– –
ITOS
91
DELISTED
iTeos Therapeutics
ITOS
$2.86M 0.02%
150,346
– –
ATRA icon
92
Atara Biotherapeutics
ATRA
$72.6M
$2.81M 0.02%
29,767
– –
TNGX icon
93
Tango Therapeutics
TNGX
$4.21B
$2.71M 0.02%
750,000
– –
SNDX icon
94
Syndax Pharmaceuticals
SNDX
$1.7B
$2.66M 0.02%
110,729
– –
OTIC
95
DELISTED
Otonomy, Inc.
OTIC
$2.49M 0.02%
8,443,134
+30,500
+0.4% +$26.7K
NGNE icon
96
Neurogene
NGNE
$669M
$2.45M 0.02%
191,087
– –
ALGS icon
97
Aligos Therapeutics
ALGS
$26.3M
$2.28M 0.02%
83,056
– –
ALEC icon
98
Alector
ALEC
$168M
$2.26M 0.01%
239,228
– –
SYRE icon
99
Spyre Therapeutics
SYRE
$8.49B
$1.79M 0.01%
136,404
– –
TCRR
100
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$1.36M 0.01%
753,064
– –
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Baker Bros. Advisors held 128 positions worth $15.3B, down 13% from $17.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q3 2022 filing shows 12 new, 7 increased, 17 reduced and 13 closed positions. Its largest new stake was Veru: 160,958 shares worth $18.5M. The largest sale was argenx, an estimated $311M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2022 buy was Veru: 160,958 shares worth $18.5M.
  • Baker Bros. Advisors added most to Rhythm Pharmaceuticals in Q3 2022, an estimated $36M increase.
  • Baker Bros. Advisors's biggest Q3 2022 reduction was argenx, cutting an estimated $311M.
  • Baker Bros. Advisors fully exited Legend Biotech in Q3 2022, selling an estimated $47.1M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $15.3B portfolio in Q3 2022.
  • Baker Bros. Advisors opened 12 new positions and closed 13 in Q3 2022.
  • Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $15.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.